Evidence map›Paper›PMID 42702937›Full record

ArticleHead & neck2026

Blueberry Extract Has Anti-Proliferative Activity in Preclinical Models of Head and Neck Cancer.

Brendan L C Kinney, Daniel Lubin, Vikash Kansal, Brianna Brammer, Jamie DeWalt, Poorvi Iyer, Chulwoo Kim, Chrystal M Paulos, Nabil F Saba, Azeem S Kaka and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Head & neck, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Brendan L C KinneyDepartment of Otolaryngology - Head and Neck Surgery, Emory University, Atlanta, Georgia, USA.ORCID https://orcid.org/0000-0002-3516-3008
Daniel LubinWinship Cancer Institute, Emory University, Atlanta, Georgia, USA.ORCID https://orcid.org/0000-0002-0409-2374
Vikash KansalDepartment of Otolaryngology - Head and Neck Surgery, Emory University, Atlanta, Georgia, USA.ORCID https://orcid.org/0000-0002-8240-2112
Brianna BrammerDepartment of Otolaryngology - Head and Neck Surgery, Emory University, Atlanta, Georgia, USA.ORCID https://orcid.org/0000-0002-3042-7326
Jamie DeWaltEmory University School of Medicine, Atlanta, Georgia, USA.ORCID https://orcid.org/0009-0004-4863-4595
Poorvi IyerUniversity of Georgia, Athens, Georgia, USA.ORCID https://orcid.org/0009-0006-8137-6924
Chulwoo KimEmory University School of Medicine, Atlanta, Georgia, USA.
Chrystal M PaulosWinship Cancer Institute, Emory University, Atlanta, Georgia, USA.
Nabil F SabaWinship Cancer Institute, Emory University, Atlanta, Georgia, USA.ORCID https://orcid.org/0000-0003-4972-1477
Azeem S KakaDepartment of Otolaryngology - Head and Neck Surgery, Emory University, Atlanta, Georgia, USA.ORCID https://orcid.org/0000-0002-4528-4460
Jennifer H GrossDepartment of Otolaryngology - Head and Neck Surgery, Emory University, Atlanta, Georgia, USA.ORCID https://orcid.org/0000-0002-4241-4821
Adam M KleinDepartment of Otolaryngology - Head and Neck Surgery, Emory University, Atlanta, Georgia, USA.
Jeffrey SwitchenkoWinship Cancer Institute, Emory University, Atlanta, Georgia, USA.ORCID https://orcid.org/0000-0002-5563-9325
Anita SethnaDepartment of Otolaryngology - Head and Neck Surgery, Emory University, Atlanta, Georgia, USA.
Fan YangWinship Cancer Institute, Emory University, Atlanta, Georgia, USA.ORCID https://orcid.org/0000-0002-2993-1023
Yong TengWinship Cancer Institute, Emory University, Atlanta, Georgia, USA.ORCID https://orcid.org/0000-0002-1856-7289
Nicole C SchmittDepartment of Otolaryngology - Head and Neck Surgery, Emory University, Atlanta, Georgia, USA.ORCID https://orcid.org/0000-0002-0571-3531

Funding

Winship Cancer Institute Cancer Center Support GrantP30CA138292 · NCI · EMORY UNIVERSITY · PI Ragini Reiney Kudchadkar · 2009 to 2026
$47.5M
Morningside Center for Innovative and Affordable MedicineNCI NIH HHS P30 CA138292NCI NIH HHS P30CA138292
6 · The paper itself

Abstract

purposeHead and neck squamous cell carcinoma (HNSCC) arises from premalignant lesions and has a high rate of disease relapse. Novel therapies are needed to treat established tumors and prevent progression of premalignant lesions.

methodsMultiple immunocompetent murine models of oral cancer were used to explore the effects of blueberry extract (BE) on tumor control and anti-tumor immune responses.

resultsBE added to drinking water provided robust tumor growth delay, resulting in frequent tumor rejection when combined with anti-PD-1 immunotherapy in one model. Tumor immune profiling, RNA sequencing, and cell depletion studies suggest that BE acts primarily via non-immune, antioxidant mechanisms. When given to mice in the 4-NQO carcinogenesis model, BE showed modest activity as a chemoprevention strategy; in a model mimicking minimal residual disease, BE showed no appreciable benefit.

conclusionsThese findings suggest that BE may have some utility as an adjunct to standard therapies for HNSCC, with limited utility during early tumorigenesis but more efficacy at later stages of tumor progression.

Indexed as

blueberry extracthead and neck cancerimmunotherapyoral cancer

Identifiers

PMID42702937
PMCPMC13580282

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.